Key updates include:

• Buprenorphine-naloxone and methadone are now recommended as first-line treatments, recognizing both as highly effective options.
• Slow-release oral morphine remains a second-line treatment.
• Withdrawal management alone is discouraged; emphasis is placed on long-term treatment for safety and recovery.
• Psychosocial support is advised but is no longer a prerequisite to accessing opioid agonist therapy.
• Harm reduction strategies are integral to patient care.

Read more and access the full guideline: National Opioid Use Disorder Guideline – CRISM